TNSN05121A1 - Purines et leurs utilisations comme ligands des recepteurs de cannabinoides - Google Patents
Purines et leurs utilisations comme ligands des recepteurs de cannabinoidesInfo
- Publication number
- TNSN05121A1 TNSN05121A1 TNP2005000121A TNSN05121A TNSN05121A1 TN SN05121 A1 TNSN05121 A1 TN SN05121A1 TN P2005000121 A TNP2005000121 A TN P2005000121A TN SN05121 A TNSN05121 A TN SN05121A TN SN05121 A1 TNSN05121 A1 TN SN05121A1
- Authority
- TN
- Tunisia
- Prior art keywords
- ligands
- purines
- cannabinoid receptors
- cannabinoid receptor
- cannabinoid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Des composés de formule (I) Qui jouent le rôle de ligands des récepteurs de cannabinoides et leurs utilisations dans le traitement de maladies en rapport avec la médiation des récepteurs de cannabinoides chez des animaux sont décrits dans le présent mémoire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42187402P | 2002-10-28 | 2002-10-28 | |
PCT/IB2003/004619 WO2004037823A1 (fr) | 2002-10-28 | 2003-10-21 | Composes puriniques et leurs utilisations comme ligands de recepteurs des cannabinoides |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN05121A1 true TNSN05121A1 (fr) | 2007-05-14 |
Family
ID=32176739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2005000121A TNSN05121A1 (fr) | 2002-10-28 | 2005-04-28 | Purines et leurs utilisations comme ligands des recepteurs de cannabinoides |
Country Status (45)
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2390496A1 (fr) * | 1999-11-12 | 2001-05-17 | Biogen, Inc. | Polycycloalkylpurines comme antagonistes du recepteur d'adenosine |
US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
US7241890B2 (en) * | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
EP1546115A4 (fr) | 2002-09-27 | 2010-08-04 | Merck Sharp & Dohme | Pyrimidines substituees |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
CA2512899A1 (fr) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7094572B2 (en) | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
CA2524397A1 (fr) * | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Ligands de recepteurs cannabinoides et leurs applications |
US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
EA010023B1 (ru) | 2003-07-14 | 2008-06-30 | Арена Фармасьютикалз, Инк. | Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
US20050043327A1 (en) * | 2003-08-21 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
JP2008517898A (ja) * | 2004-10-22 | 2008-05-29 | ファイザー・プロダクツ・インク | プリン化合物を調製するための方法 |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
AR051596A1 (es) * | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
WO2006054057A2 (fr) * | 2004-11-16 | 2006-05-26 | Gw Pharma Limited | Nouvelle utilisation des cannabinoides |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
EP1874779A1 (fr) * | 2005-04-20 | 2008-01-09 | Pfizer Products Inc. | Composes heteromatiques acylaminobicycliques tenant lieu de ligands du recepteur cannabinoide |
EP1890767A2 (fr) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combinaison d'un antagoniste des recepteurs cannabinoides-1 et d'un inhibiteur des proteines microsomales de transfert de triglycerides pour traiter l'obesite ou maintenir une perte de poids |
AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
JP5400388B2 (ja) | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ, インコーポレイテッド | キナーゼインヒビターおよびその利用 |
AU2006331917A1 (en) * | 2005-12-22 | 2007-07-05 | Conforma Therapeutics Corporation | Orally active purine-based inhibitors of heat shock protein 90 |
AU2007222069A1 (en) * | 2006-02-21 | 2007-09-13 | Ampla Pharmaceuticals Inc. | CB1 antagonists and inverse agonists |
US8138188B2 (en) | 2006-02-23 | 2012-03-20 | Pfizer Inc. | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
ES2878130T3 (es) | 2006-04-25 | 2021-11-18 | Astex Therapeutics Ltd | Derivados de purina y deazapurina como compuestos farmacéuticos |
WO2008044111A1 (fr) * | 2006-10-13 | 2008-04-17 | Pfizer Products Inc. | Cachet de formulation pharmaceutique |
AU2007320906A1 (en) | 2006-11-13 | 2008-05-22 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
EP2094643B1 (fr) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | Inhibiteurs d'amino cetp étendus |
AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
PL2114933T3 (pl) | 2007-01-04 | 2012-02-29 | Prosidion Ltd | Piperydyny jako agoniści GPCR |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
BRPI0806312A2 (pt) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
US20080220104A1 (en) * | 2007-03-08 | 2008-09-11 | Cappello John V | Compositions for producing satiety |
AU2008307798B2 (en) | 2007-10-05 | 2013-10-03 | Verastem, Inc. | Pyrimidine substituted purine derivatives |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
MX2010005648A (es) * | 2007-11-21 | 2010-06-02 | Abbott Lab | Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina. |
JP2010043063A (ja) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
AU2009278838B2 (en) | 2008-08-06 | 2013-07-25 | Pfizer Limited | Diazepine and diazocane compounds as MC4 agonists |
WO2010019762A1 (fr) * | 2008-08-13 | 2010-02-18 | Jenrin Discovery | Composés de purine en tant que bloqueurs de récepteur aux cannabinoïdes |
AU2009308675A1 (en) | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine JAK inhibitor compounds and methods |
UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
EP2246335A1 (fr) * | 2009-02-17 | 2010-11-03 | Bayer CropScience AG | Aminopyridineamides en tant que pesticides |
US8754080B2 (en) | 2009-04-03 | 2014-06-17 | Verastem, Inc. | Pyrimidine substituted purine compounds as kinase (S) inhibitors |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
WO2011059207A2 (fr) | 2009-11-13 | 2011-05-19 | Green Cross Corporation | Dérivés de purine contenant une arylpipérazine et leurs applications |
MX2012010265A (es) * | 2010-03-17 | 2012-10-01 | Hoffmann La Roche | Compuestos de imidazopiridina, composiciones y metodos de uso. |
MX2012011164A (es) | 2010-03-31 | 2012-11-12 | Lilly Co Eli | Compuesto de purina usados como agonistas de cb2. |
AR080711A1 (es) | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
JP2013528598A (ja) | 2010-05-11 | 2013-07-11 | ファイザー・インク | ミネラルコルチコイド受容体拮抗薬としてのモルホリン化合物 |
TW201217387A (en) | 2010-09-15 | 2012-05-01 | Hoffmann La Roche | Azabenzothiazole compounds, compositions and methods of use |
EP2619198A1 (fr) | 2010-09-22 | 2013-07-31 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés |
CA2817785A1 (fr) | 2010-11-19 | 2012-05-24 | Toby Blench | Pyrazolopyridines, et pyrazolopyridines et leur utilisation en tant qu'inhibiteurs de tyk2 |
WO2013041539A1 (fr) * | 2011-09-20 | 2013-03-28 | F. Hoffmann-La Roche Ag | Composé imidazopyridine, compositions et procédés d'utilisation |
CZ305750B6 (cs) * | 2012-01-26 | 2016-03-02 | Ústav Organické Chemie A Biochemie Akademie Věd Čr, V.V.I. | Způsob výroby N-9 substituovaných analogů purinu |
WO2013123335A1 (fr) | 2012-02-17 | 2013-08-22 | Research Triangle Institute | Dérivés de diphényle purine restreints de manière périphérique |
RU2485939C1 (ru) * | 2012-06-19 | 2013-06-27 | Станислав Анатольевич Кедик | Офтальмологический препарат в виде глазных капель, содержащий дисульфирам и таурин |
WO2014177490A1 (fr) | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Dérivés de la purine en tant qu'agonistes du récepteur cb2 |
AU2015217802B2 (en) | 2014-02-17 | 2019-06-06 | Bayer Cropscience Aktiengesellschaft | 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents |
MX2016015062A (es) | 2014-05-23 | 2017-02-27 | Hoffmann La Roche | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina los cuales son inhibidores de janus cinasas (jak). |
MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
CN104581617A (zh) * | 2015-01-22 | 2015-04-29 | 小米科技有限责任公司 | 无线通信方法和智能设备 |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
AU2017382217B2 (en) * | 2016-12-21 | 2021-07-08 | Research Triangle Institute | Diaryl purine derivatives with improved bioavailability |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
TW201902896A (zh) | 2017-05-22 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療化合物及組合物及其使用方法 |
WO2020148760A1 (fr) * | 2019-01-15 | 2020-07-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Bloqueurs du récepteur cb 1 à chaînes principales acycliques |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3018378A (en) * | 1954-09-20 | 1962-01-23 | North American Aviation Inc | Radiant energy scanning system |
US3016378A (en) | 1959-07-01 | 1962-01-09 | Thomae Gmbh Dr K | Amino-substituted purine derivatives |
GB1165283A (en) | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
AT321295B (de) | 1971-11-11 | 1975-03-25 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen Thiazolo[5,4-d]-pyrimidin-Derivaten und ihren Salzen |
CH653021A5 (fr) | 1981-04-24 | 1985-12-13 | Delalande Sa | Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant. |
JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
GB8613591D0 (en) | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
ES2037739T3 (es) | 1986-10-22 | 1993-07-01 | Ciba-Geigy Ag | Derivados del acido 1,5-difenilpirazol-3-carboxilico para la proteccion de plantas de cultivo. |
AU611437B2 (en) | 1987-05-29 | 1991-06-13 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same |
US5057517A (en) | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5256398A (en) | 1990-11-08 | 1993-10-26 | Whitby Research, Inc. | Composition for determining viability of tissue |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
EP0915093B1 (fr) | 1996-06-06 | 2002-11-27 | Otsuka Pharmaceutical Factory, Inc. | Derives d'amides |
US6100259A (en) | 1997-01-21 | 2000-08-08 | Smithkline Beecham Corporation | Cannabinoid receptor modulators |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
WO1998039344A1 (fr) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase |
FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
JP3990061B2 (ja) * | 1998-01-05 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンa2受容体拮抗剤 |
ATE242775T1 (de) | 1998-01-05 | 2003-06-15 | Eisai Co Ltd | Purinderivate und antagonisten des adenosin-a2- rezeptors, welche zur vorsorge oder heilung von diabetes dienen |
IL141769A0 (en) | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
US6841549B1 (en) * | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
FR2799124B1 (fr) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
MXPA02005101A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Derivados de indol canabimimeticos. |
JP2003512357A (ja) | 1999-10-18 | 2003-04-02 | ユニバーシティ オブ コネチカット | カンナビノイドレセプタ拮抗物質としてのピラゾール誘導体 |
FR2800372B1 (fr) | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
AU2001234958A1 (en) | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
US6355631B1 (en) | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
US6479479B2 (en) | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
MXPA02009258A (es) | 2000-03-23 | 2005-04-19 | Solvay Pharm Bv | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonistica de cannabis-1. |
FR2809621B1 (fr) | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques |
US20020019421A1 (en) | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
CN1274690C (zh) | 2000-12-28 | 2006-09-13 | 小野药品工业株式会社 | 三杂环化合物和包括其作为活性组分的药物 |
ES2229132T3 (es) | 2001-03-22 | 2005-04-16 | Solvay Pharmaceuticals B.V. | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad como antagonistas de cb1. |
ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
WO2003007887A2 (fr) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
CA2457922A1 (fr) | 2001-08-31 | 2003-03-13 | University Of Connecticut | Nouveaux analogues de pyrazole agissant sur les recepteurs cannabinoides |
SI1429761T1 (sl) | 2001-09-21 | 2007-02-28 | Solvay Pharm Bv | Novi 4,5-dihidro-1h-pirazolni derivati s cb1-antagonisticno aktivnostjo |
IL157704A0 (en) | 2001-09-21 | 2004-03-28 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
HN2002000266A (es) | 2001-09-24 | 2003-11-16 | Bayer Corp | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad. |
US20040267028A1 (en) | 2001-09-24 | 2004-12-30 | Smith Roger A | Preparation and use of pyrrole derivatives for treating obesity |
ATE311386T1 (de) | 2001-09-24 | 2005-12-15 | Bayer Pharmaceuticals Corp | Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit |
SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
US20030139386A1 (en) | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
US20050171161A1 (en) | 2002-03-06 | 2005-08-04 | Fong Tung M. | Method of treatment or prevention of obesity |
WO2003077847A2 (fr) | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Amides substitues |
AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
AU2003215024B2 (en) | 2002-03-26 | 2008-02-21 | Merck Sharp & Dohme Corp. | Spirocyclic amides as cannabinoid receptor modulators |
ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
JP2005531520A (ja) | 2002-03-28 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | 置換2,3−ジフェニルピリジン類 |
FR2837706A1 (fr) | 2002-03-28 | 2003-10-03 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles |
CA2480856A1 (fr) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Arylamides substituee |
FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
DE60314623T2 (de) | 2002-05-10 | 2008-02-28 | Smithkline Beecham Corp. | Substituierte pyrazolopyrimidine |
AU2003267728A1 (en) | 2002-10-18 | 2004-05-04 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US20050043327A1 (en) * | 2003-08-21 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
JP2008517898A (ja) * | 2004-10-22 | 2008-05-29 | ファイザー・プロダクツ・インク | プリン化合物を調製するための方法 |
-
2003
- 2003-10-20 US US10/689,381 patent/US7129239B2/en not_active Expired - Fee Related
- 2003-10-21 EA EA200500520A patent/EA008176B1/ru not_active IP Right Cessation
- 2003-10-21 CN CNA2006101625782A patent/CN1955181A/zh active Pending
- 2003-10-21 JP JP2004546275A patent/JP3954618B2/ja not_active Expired - Fee Related
- 2003-10-21 EP EP03751149A patent/EP1558615B8/fr not_active Expired - Lifetime
- 2003-10-21 PL PL03376311A patent/PL376311A1/xx not_active Application Discontinuation
- 2003-10-21 CN CNB2006101625797A patent/CN100478343C/zh not_active Expired - Fee Related
- 2003-10-21 ES ES03751149T patent/ES2291669T3/es not_active Expired - Lifetime
- 2003-10-21 SG SG200703819-3A patent/SG148071A1/en unknown
- 2003-10-21 CA CA002503900A patent/CA2503900C/fr not_active Expired - Fee Related
- 2003-10-21 OA OA1200500128A patent/OA13080A/en unknown
- 2003-10-21 MX MXPA05003882A patent/MXPA05003882A/es active IP Right Grant
- 2003-10-21 CN CNB2003801022192A patent/CN100439369C/zh not_active Expired - Fee Related
- 2003-10-21 AU AU2003269368A patent/AU2003269368B2/en not_active Ceased
- 2003-10-21 UA UAA200504047A patent/UA79507C2/uk unknown
- 2003-10-21 WO PCT/IB2003/004619 patent/WO2004037823A1/fr active IP Right Grant
- 2003-10-21 AT AT03751149T patent/ATE371658T1/de active
- 2003-10-21 KR KR1020057007317A patent/KR100674560B1/ko not_active IP Right Cessation
- 2003-10-21 AP AP2005003290A patent/AP1916A/xx active
- 2003-10-21 PT PT03751149T patent/PT1558615E/pt unknown
- 2003-10-21 DK DK03751149T patent/DK1558615T3/da active
- 2003-10-21 NZ NZ539589A patent/NZ539589A/en not_active IP Right Cessation
- 2003-10-21 RS YUP-2005/0306A patent/RS20050306A/sr unknown
- 2003-10-21 DE DE60316012T patent/DE60316012T2/de not_active Expired - Lifetime
- 2003-10-21 BR BR0314918-8A patent/BR0314918A/pt not_active IP Right Cessation
- 2003-10-21 GE GEAP20038773A patent/GEP20084325B/en unknown
- 2003-10-22 DO DO2003000742A patent/DOP2003000742A/es unknown
- 2003-10-22 TW TW092129337A patent/TWI327567B/zh not_active IP Right Cessation
- 2003-10-23 MY MYPI20034057A patent/MY140010A/en unknown
- 2003-10-24 PE PE2003001082A patent/PE20040781A1/es not_active Application Discontinuation
- 2003-10-27 EG EG2003101003A patent/EG24662A/xx active
- 2003-10-27 AR ARP030103918A patent/AR041835A1/es active IP Right Grant
- 2003-10-27 GT GT200300232A patent/GT200300232A/es unknown
- 2003-10-27 UY UY28044A patent/UY28044A1/es not_active Application Discontinuation
- 2003-10-28 NL NL1024643A patent/NL1024643C2/nl not_active IP Right Cessation
- 2003-11-14 RS YUP-2005/0395A patent/RS20050395A/sr unknown
-
2005
- 2005-04-14 IS IS7801A patent/IS2602B/is unknown
- 2005-04-15 CU CU20050077A patent/CU23535A3/es not_active IP Right Cessation
- 2005-04-26 ZA ZA200503378A patent/ZA200503378B/en unknown
- 2005-04-27 CO CO05040051A patent/CO5560546A2/es not_active Application Discontinuation
- 2005-04-28 MA MA28239A patent/MA27479A1/fr unknown
- 2005-04-28 TN TNP2005000121A patent/TNSN05121A1/fr unknown
- 2005-04-28 EC EC2005005767A patent/ECSP055767A/es unknown
- 2005-04-28 CR CR7812A patent/CR7812A/es unknown
- 2005-04-28 HR HR20050378A patent/HRP20050378A2/hr not_active Application Discontinuation
- 2005-05-25 NO NO20052512A patent/NO332195B1/no not_active IP Right Cessation
-
2006
- 2006-01-26 HK HK06101184.8A patent/HK1081189A1/xx not_active IP Right Cessation
- 2006-07-10 US US11/456,406 patent/US20060241120A1/en not_active Abandoned
- 2006-12-12 JP JP2006334714A patent/JP2007099779A/ja active Pending
-
2007
- 2007-07-03 HK HK07107063.0A patent/HK1099762A1/xx not_active IP Right Cessation
- 2007-10-19 CY CY20071101350T patent/CY1107505T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN05121A1 (fr) | Purines et leurs utilisations comme ligands des recepteurs de cannabinoides | |
TNSN05190A1 (fr) | DERIVES DE PYRAZOLO [1,5-a][1,3,5] TRIAZINE SERVANT DE LIGANDS DES RECEPTEURS DE CANNABINOIDES | |
MA27767A1 (fr) | Ligands des recepteurs de cannabinoides et leurs utilisations | |
TNSN03142A1 (fr) | Ligands des recepteurs de 5-ht et leurs utilisations | |
TNSN05272A1 (fr) | Ligands de recepteurs de cannabinoides et leurs utilisations | |
MA28681B1 (fr) | 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines | |
TNSN05317A1 (fr) | Ligands des recepteurs de cannabinoides et leurs utilisations | |
MA28680B1 (fr) | 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines | |
MXPA05013282A (es) | Derivados de pirimidina como ligandos del receptor de cannabinoides. | |
MA29354B1 (fr) | Derives de cyclopentapyridine et tetrahydroquinoleine. | |
HRP20040684A2 (en) | 2,4-pyrimidinediamine compounds and their uses | |
WO2007020502A3 (fr) | Ligands des recepteurs de cannabinoide et utilisations de ceux-ci | |
TN2012000073A1 (fr) | Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119 | |
MY137053A (en) | Pyrimidine derivatives and their use as cb2 modulators | |
TNSN06368A1 (fr) | 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines | |
MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
EA200800664A1 (ru) | Производные пирролопиримидина в качестве ингибиторов syk | |
ATE368034T1 (de) | Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase | |
EA200600647A1 (ru) | Соединения бициклических пиразолила и имидазолила и их применение | |
MA30485B1 (fr) | Aminothiazoles et leurs utilisations | |
ATE489361T1 (de) | Derivate von alpha-phenylthiocarbon- und alpha- phenyloxycarbonsäuren, die für die behandlung von auf die aktivierung von ppar alpha ansprechende krankheiten geeignet sind | |
MA31562B1 (fr) | Macrocycles et leurs utilisations | |
ATE353648T1 (de) | Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten | |
TNSN06444A1 (fr) | 3-aminocyclopentanecarboxamides utiles comme modulateurs de recepteurs de chimiokines |